评价dirlotapide持续减肥体重超重的拉布拉多猎犬。

文章的细节

引用

复制到剪贴板

Gossellin J,皮奇年代,Sherington J,罗文TG,桑德兰SJ

评价dirlotapide持续减肥体重超重的拉布拉多猎犬。

J兽医杂志。2007年8月,30增刊55 - 65。

PubMed ID

17567515 (在PubMed

]

文摘

dirlotapide的影响体重(BW)减少了在两个parallel-design研究超重的拉布拉多犬。研究涉及42个狗随机到0.0,0.025,0.05,0.1,0.2或0.4毫克dirlotapide口头/公斤/天4周。研究涉及B 72只狗随机9治疗:安慰剂(24周);dirlotapide(24周)其次是安慰剂(28周);或dirlotapide(52周);在饮食含5%,10%或15%的脂肪。最初Dirlotapide剂量(0.1毫克/公斤)调整每月在24周的减肥和随后的28 weight-stabilization阶段。食物提供以上维护能源需求基于初始BW (MERx 1.1 - -1.2)。身体成分(脂肪,精益组织和骨矿物质含量)是使用双能x线吸收仪监测。治疗后,狗收到dirlotapide 52周美联储90%的数量消耗在52周。 In study A, BW and food intake decreased asymptotically with dose: mean weekly weight loss exceeded 1% at 0.1-0.4 mg/kg. In study B, dirlotapide resulted in significant mean weekly weight loss (>0.8%) and decreased food intake over 24 weeks compared with placebo (P = 0.0001) for all diets. Food restriction minimized post-treatment weight rebound. Dirlotapide administered daily to dogs for up to 52 weeks was clinically safe and resulted in sustained weight reduction.

DrugBank数据引用了这篇文章

药物

Dirlotapide